drugset / Trial / NCT05716100
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RandomizedParallel-groupDouble-blindTreatment
Summary
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Timeline
- Start
- 2023-05-09
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 15 mg | Oral |
| Subject | Azetukalner | Small molecule | 25 mg | Oral |